aprepitant (Emend) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Aprepitant, sold under the brand name Emend among others, is a medication used to prevent chemotherapy-induced nausea and vomiting (CINV) and to prevent postoperative nausea and vomiting (PONV). It may be used together with ondansetron and dexamethasone. It is taken by mouth or administered by intravenous injection.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.2837 - $322.9300

Australia

$51.9296 - $80.9956
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine | ((2r)-(1r)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(s)-(4-fluoro)phenyl-4-(3-(1-phosphoryl-5-oxo-4h-1,2,4-triazolo))methylmorpholine | (2r)-(1r)-3,5-bis(trifluoromethylphenyl)ethoxy)-(3s)-(4-fluoro)phenyl-4-(3-(5-oxo-1h,4h-1,2,4-triazole)methyl-morpholine | 3-(((2r,3s)-3-(p-fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one | aprepitant | aprépitant | aprepitantum | apretpitant | emend | emend for injection | fosaprepitant | fosaprepitant dimeglumine | fosaprepitant meglumine | fosaprepitantum | ivemend | l 754030 | l 754,030 | l-754030 | l-754,030 | l758298 | l 758298 | l-758,298 | l 785,298 | l-785,298 | l785,298 | mk0517 | mk 0517 | mk-0517 | mk0869 | mk 0869 | mk-0869 | mk 869 | mk-869 | nk1 antagonist | ono-7436

Organizations (200)

Research & Development (174)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (29)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (70)

Approved Indications (4)


 

Leukemia, Myeloid, Acute

Nausea (approved 2008)

Neoplasms

Postoperative Nausea and Vomiting

Experimental Indications - Clinical Trial Phases 1-4 (70)


 

Aggression (Phase 1/Phase 2)

Alcoholism (Phase 2)

Analgesia (Phase 2)

Antiemetics (Phase 3)

Bariatric Surgery (Phase 4)

Bile Duct Neoplasms (Phase 2)

Brain Injuries, Traumatic (Early Phase 1)

Breast Neoplasms (Phase 4)

Cannabis (Phase 2)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 2)

Cholangiocarcinoma (Phase 2)

Cocaine-Related Disorders (Phase 2)

Colonic Neoplasms (Phase 2/Phase 3)

Colorectal Neoplasms (Phase 3)

COVID-19 (Phase 2)

Depressive Disorder, Major (Phase 3)

Diabetes Mellitus, Type 2 (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Drug Therapy (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Gastroparesis (Phase 3)

General Surgery (Phase 3)

Genital Neoplasms, Female (Phase 3)

Glioblastoma (Phase 1)

Glioma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 4)

Heart Failure (Phase 4)

Hematologic Diseases (Phase 2)

Heroin Dependence (Phase 1)

HIV Infections (Phase 1)

Hypertension (Phase 2)

Laparoscopy (Phase 4)

Leukemia (Phase 4)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 4)

Lymphoma, Non-Hodgkin (Phase 1)

Marijuana Abuse (Phase 2)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 3)

Nasopharyngeal Carcinoma (Phase 1)

Nasopharyngeal Neoplasms (Phase 3)

Nausea ()

Neoadjuvant Therapy (Phase 2)

Neoplasms ()

Neoplasms, Germ Cell and Embryonal (Phase 3)

Obesity (Phase 4)

Opioid-Related Disorders (Phase 1)

Ovarian Neoplasms (Phase 4)

Pain, Postoperative (Phase 2)

Pancreatic Neoplasms (Phase 3)

Parkinson Disease (Phase 2)

Postoperative Complications (Phase 4)

Postoperative Nausea and Vomiting ()

Pruritus (Phase 4)

Radiation (Phase 3)

Sarcoma (Phase 2)

Sezary Syndrome (Phase 4)

Stress Disorders, Post-Traumatic (Phase 2)

Substance-Related Disorders (Phase 1)

Substance Withdrawal Syndrome (Phase 1)

Tobacco Use Disorder (Phase 1)

Uterine Cervical Neoplasms (Phase 3)

Uterine Neoplasms (Phase 4)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 213
  • # of Trial Organizations: 174

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue